Standard Operating Procedure for Selecting Host Cell Lines in Biosimilar Manufacturing

1. Purpose

To establish a standardized procedure for selecting host cell lines such as CHO, HEK293, and E. coli for the development of biosimilars, ensuring high productivity, regulatory compliance, and reproducibility.

2. Scope

This SOP applies to all personnel in the Biosimilars department involved in the selection, evaluation, and documentation of host cell lines during early-stage biosimilar development.

3. Responsibilities

• Research Scientists: Perform literature review and technical assessments for host cell line suitability.
• Process Development Team: Conduct experimental validation of expression and growth performance.
• Regulatory Affairs (RA): Ensure the selected cell lines meet global regulatory and biosafety standards.
• Quality Assurance (QA): Review and archive all documentation related to cell line selection.

4. Accountability

The Head of Biosimilars is accountable for ensuring compliance with this SOP and the scientific and regulatory appropriateness of the host cell lines selected.

5. Procedure

5.1 Define Product Requirements

1. Identify the biosimilar product type: e.g., monoclonal antibody, cytokine, or hormone.
2. Define requirements for post-translational modifications such as glycosylation.
3. Establish expression yield targets based on commercial-scale requirements.

5.2 Compile List of Candidate Host Cell Lines

1. Generate a list of commonly used host cell lines:
   • CHO (Chinese Hamster Ovary)
   • HEK293 (Human Embryonic Kidney)
   • E. coli (for prokaryotic expression)
2. Assess each host cell line based on:
   • Scalability
   • Doubling time and metabolic efficiency
   • Post-translational modification capabilities
   • Availability of safety and lineage documentation

5.3 Perform Feasibility Experiments

1. Perform small-scale transfection experiments with model constructs.
2. Measure protein expression levels using ELISA or SDS-PAGE.
3. Record findings in the Host Cell Screening Log (Annexure-1).

5.4 Review Regulatory and Biosafety Compliance

1. Check biosafety levels (BSL-1 or BSL-2) of selected cell lines.
2. Ensure the availability of cell bank Certificate of Analysis (CoA).
3. Verify compliance with ICH Q5D, WHO TRS 978, and CDSCO requirements.

5.5 Final Selection and Approval

1. Consolidate all experimental, regulatory, and biosafety data.
2. Complete the Host Cell Line Selection Form (Annexure-2).
3. Submit the form for cross-functional review and approval.

5.6 Documentation

1. Update the Host Cell Line Master List (Annexure-3).
2. File all relevant data in the Cell Line Selection Master File.

6. Abbreviations

• SOP: Standard Operating Procedure
• CHO: Chinese Hamster Ovary
• HEK293: Human Embryonic Kidney 293
• CoA: Certificate of Analysis
• RA: Regulatory Affairs
• QA: Quality Assurance

7. Documents

1. Host Cell Screening Log (Annexure-1)
2. Host Cell Line Selection Form (Annexure-2)
3. Host Cell Line Master List (Annexure-3)

8. References

• ICH Q5D: Cell Substrate Derivation and Characterization
• WHO TRS 978 Annex 3
• CDSCO Guidelines – Cell Line Selection (India)

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Host Cell Screening Log

Annexure-2: Host Cell Line Selection Form

Annexure-3: Host Cell Line Master List

Revision History:

Standard Operating Procedure for Gene Synthesis and Sequence Verification in Biosimilar Development

1. Purpose

To describe the standardized procedure for gene synthesis and verification of nucleotide sequences to ensure fidelity and regulatory compliance in biosimilar product development.

2. Scope

This SOP is applicable to the Biosimilars R&D and Molecular Biology teams responsible for designing, outsourcing, receiving, and verifying gene constructs used in biosimilar expression systems.

3. Responsibilities

• Molecular Biologist: Designs gene sequences and validates synthetic constructs post-delivery.
• R&D Scientist: Initiates synthesis requests and coordinates with vendors.
• QA: Reviews sequence verification reports and documentation.

4. Accountability

The Head of Biosimilars R&D is accountable for ensuring that gene constructs are correctly synthesized and sequence-verified prior to downstream applications.

5. Procedure

5.1 Gene Design and Optimization

1. Design the coding sequence of the biosimilar target protein based on reference sequence from public databases (e.g., GenBank).
2. Use codon optimization tools to adapt the sequence to the host expression system (CHO, E. coli, HEK293).
3. Ensure inclusion of necessary elements such as restriction sites, Kozak sequence, or signal peptides as per application.

5.2 Sequence Validation and Approval

1. Submit the final DNA construct design for internal review using the Gene Design Approval Form (Annexure-1).
2. Obtain QA clearance for synthesis initiation.

5.3 Ordering and Vendor Management

1. Select vendor based on approved supplier list for gene synthesis (e.g., GenScript, IDT).
2. Place purchase order specifying:
   • Sequence length and cloning vector
   • Restriction sites and tags
   • Required delivery format (plasmid or lyophilized)
3. Maintain vendor communication log (Annexure-2).

5.4 Receipt and Initial Inspection

1. On receipt, verify labeling, packaging, and physical integrity.
2. Cross-check delivered sequence with purchase order.
3. Record in Gene Receipt Log (Annexure-3).

5.5 Sequence Verification

1. Extract plasmid DNA using miniprep kit.
2. Perform Sanger sequencing using M13 or specific primers.
3. Align sequencing chromatogram with reference design using tools such as SnapGene or BLAST.
4. Document base accuracy and mutations (if any) in the Sequence Verification Report (Annexure-4).

5.6 Discrepancy Handling

1. In case of mismatch:
   • Notify vendor immediately.
   • Reorder corrected construct after necessary approvals.

5.7 Archiving and Documentation

1. Store physical DNA sample in -20°C plasmid archive with label and code.
2. Archive all sequence files (.ab1, .seq), order forms, and approval documents.

6. Abbreviations

• SOP: Standard Operating Procedure
• QA: Quality Assurance
• R&D: Research and Development
• BLAST: Basic Local Alignment Search Tool

7. Documents

1. Gene Design Approval Form (Annexure-1)
2. Vendor Communication Log (Annexure-2)
3. Gene Receipt Log (Annexure-3)
4. Sequence Verification Report (Annexure-4)

8. References

• ICH Q5B: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products
• WHO Guidelines on DNA Vaccines and Plasmid Vectors
• CDSCO India Guidance on Genetic Engineering Techniques

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Gene Design Approval Form

Annexure-2: Vendor Communication Log

Annexure-3: Gene Receipt Log

Annexure-4: Sequence Verification Report

Revision History:

Standard Operating Procedure for Vector Design and Cloning in Biosimilar Research

1. Purpose

To describe the procedure for designing plasmid expression vectors and performing gene cloning required for biosimilar development, ensuring proper integration, regulatory compliance, and traceability of constructs.

2. Scope

This SOP is applicable to R&D personnel in the Biosimilars department who are involved in cloning biosimilar gene constructs into vectors for expression in host cell lines such as CHO, HEK293, or E. coli.

3. Responsibilities

• Molecular Biology Scientist: Designs vector maps, selects restriction sites, and performs ligation.
• Research Assistant: Executes the cloning process and confirms insert integration.
• QA Representative: Verifies and approves cloning results and sequence confirmations.

4. Accountability

The Head of Molecular Biology is accountable for ensuring cloning procedures are conducted as per defined protocols and all documentation is complete and accurate.

5. Procedure

5.1 Vector Backbone Selection

1. Select suitable plasmid backbone (e.g., pcDNA3.1, pET28a, pCMV6) based on host system and expression requirements.
2. Confirm:
   • Selectable marker (Ampicillin, Kanamycin, Hygromycin)
   • Promoter compatibility (CMV, T7, EF-1α)
   • Multiple Cloning Site (MCS) availability

5.2 Insert Preparation

1. Obtain synthesized gene insert or PCR-amplify target gene with designed primers.
2. Incorporate restriction enzyme recognition sites during primer design (e.g., EcoRI, HindIII).
3. Purify PCR product using a column purification kit and verify via agarose gel electrophoresis.

5.3 Vector Linearization

1. Digest the plasmid backbone with appropriate restriction enzymes.
2. Perform double digestion, if required, to prevent vector re-ligation.
3. Purify digested vector using gel extraction method.

5.4 Ligation of Insert into Vector

1. Set up ligation reaction using T4 DNA ligase at the recommended molar ratio (insert:vector = 3:1).
2. Incubate ligation reaction at 16°C overnight or at room temperature for 2 hours.

5.5 Transformation and Colony Screening

1. Transform ligation mix into competent E. coli DH5α cells.
2. Plate on antibiotic selection agar plates and incubate overnight at 37°C.
3. Pick colonies and inoculate into LB broth with appropriate antibiotic.

5.6 Confirmation of Cloning

1. Extract plasmid DNA using miniprep kit.
2. Verify insert via:
   • Restriction digestion pattern
   • PCR using gene-specific primers
   • Sanger sequencing for sequence confirmation
3. Record results in Cloning Verification Report (Annexure-1).

5.7 Storage and Documentation

1. Store confirmed clones in glycerol stocks at -80°C (Annexure-2: Clone Stock Log).
2. Archive sequencing results and annotated vector maps in shared database.

6. Abbreviations

• SOP: Standard Operating Procedure
• MCS: Multiple Cloning Site
• CMV: Cytomegalovirus Promoter
• PCR: Polymerase Chain Reaction
• QA: Quality Assurance

7. Documents

1. Cloning Verification Report (Annexure-1)
2. Clone Stock Log (Annexure-2)
3. Vector Design Checklist (Annexure-3)

8. References

• ICH Q5B: Expression Construct Analysis Guidelines
• WHO TRS 978 Annex on Recombinant Technology
• CDSCO Guidelines on Recombinant Product Development

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Cloning Verification Report

Annexure-2: Clone Stock Log

Annexure-3: Vector Design Checklist

Revision History:

Standard Operating Procedure for Preparation of Competent Cells in Biosimilar R&D

1. Purpose

To define the process for preparing chemically and electrocompetent E. coli cells for use in transformation procedures during biosimilar molecular biology workflows.

2. Scope

This SOP applies to laboratory personnel involved in preparing and storing competent bacterial cells within the Biosimilars R&D facility.

3. Responsibilities

• Research Associate: Carries out the competent cell preparation procedure and maintains documentation.
• Laboratory Technician: Prepares media and buffers, ensures sterile conditions, and labels vials.
• QA Officer: Verifies batch records and checks viability logs.

4. Accountability

The Head of Molecular Biology is accountable for ensuring that all competent cell preparations meet quality and transformation efficiency requirements.

5. Procedure

5.1 Reagents and Materials Required

• SOB medium or LB broth
• Calcium chloride (CaCl₂) solution (100 mM)
• Glycerol (10%) for storage
• Electroporation buffer (if preparing electrocompetent cells)
• Ice, sterile tubes, centrifuge

5.2 Culture Growth

1. Inoculate a single colony of E. coli DH5α into 5 mL LB broth and incubate overnight at 37°C with shaking (200 rpm).
2. Dilute 1:100 into 100 mL fresh LB medium and grow until OD₆₀₀ reaches 0.4–0.6.

5.3 Preparation of Chemically Competent Cells

1. Chill the culture on ice for 10–15 minutes.
2. Centrifuge at 4,000 rpm for 10 minutes at 4°C.
3. Discard supernatant and gently resuspend pellet in 50 mL of ice-cold 100 mM CaCl₂.
4. Incubate on ice for 30 minutes.
5. Repeat centrifugation and resuspend in 10 mL of ice-cold 100 mM CaCl₂ + 15% glycerol.
6. Aliquot 100 µL per sterile microcentrifuge tube and flash freeze in liquid nitrogen.
7. Store at -80°C.

5.4 Preparation of Electrocompetent Cells

1. Harvest cells as above once OD₆₀₀ reaches 0.5.
2. Wash cells three times with ice-cold sterile 10% glycerol.
3. Resuspend final pellet in 1 mL ice-cold 10% glycerol.
4. Aliquot into pre-chilled sterile tubes (50 µL each) and store at -80°C.

5.5 Documentation and Quality Check

1. Label all tubes with strain name, date, and preparation type (chemically/electrocompetent).
2. Log entries in Competent Cell Preparation Log (Annexure-1).
3. Test transformation efficiency using a standard plasmid (e.g., pUC19) and record in Transformation Efficiency Report (Annexure-2).

6. Abbreviations

• SOP: Standard Operating Procedure
• OD₆₀₀: Optical Density at 600 nm
• QA: Quality Assurance

7. Documents

1. Competent Cell Preparation Log (Annexure-1)
2. Transformation Efficiency Report (Annexure-2)

8. References

• ICH Q5A: Viral Safety Evaluation of Biotechnology Products
• WHO Guidelines for Recombinant DNA Products
• CDSCO Laboratory Practice Manual

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Competent Cell Preparation Log

Annexure-2: Transformation Efficiency Report

Revision History:

Standard Operating Procedure for Transformation and Electroporation in Biosimilar Development

1. Purpose

To outline the standardized procedure for introducing recombinant plasmids into host cells using chemical transformation and electroporation methods in biosimilar development workflows.

2. Scope

This SOP is applicable to laboratory personnel involved in bacterial transformation processes using competent E. coli strains within the Biosimilars R&D facility.

3. Responsibilities

• Research Associate: Performs transformation and electroporation procedures.
• Technician: Prepares reagents and media, and assists in plate incubation and recovery steps.
• QA Officer: Reviews transformation efficiency and compliance documentation.

4. Accountability

The Head of Biosimilars R&D is accountable for ensuring that transformation protocols are conducted according to validated procedures and that resulting data is accurately recorded.

5. Procedure

5.1 Materials Required

• Chemically competent or electrocompetent E. coli cells
• Plasmid DNA (purified)
• SOC medium
• Agar plates with appropriate antibiotic
• Electroporator (for electroporation method)

5.2 Chemical Transformation Procedure

1. Thaw 100 µL of chemically competent cells on ice.
2. Add 1–5 ng of plasmid DNA gently and mix by tapping.
3. Incubate the mixture on ice for 30 minutes.
4. Heat shock at 42°C for 45 seconds.
5. Immediately transfer tubes to ice for 2 minutes.
6. Add 900 µL of SOC medium and incubate at 37°C for 1 hour with shaking (200 rpm).
7. Plate 100–200 µL on LB agar containing the appropriate antibiotic.
8. Incubate overnight at 37°C.

5.3 Electroporation Procedure

1. Thaw 50 µL of electrocompetent cells on ice.
2. Add 1–2 µL of plasmid DNA, mix gently.
3. Transfer to pre-chilled 0.1 cm electroporation cuvette.
4. Electroporate at 1.8 kV, 25 µF, 200 ohms (or follow equipment-specific settings).
5. Immediately add 950 µL of SOC medium and transfer to sterile tube.
6. Recover at 37°C for 1 hour, shaking at 200 rpm.
7. Plate appropriate volumes on selective agar and incubate overnight.

5.4 Post-Transformation Analysis

1. Count colonies and record transformation efficiency using formula:
   
   Efficiency (cfu/µg DNA) = (colonies × dilution factor) / amount of DNA (µg)
2. Log entries in Transformation Logbook (Annexure-1).

5.5 Storage and Record Keeping

1. Inoculate confirmed transformants into LB broth and prepare glycerol stocks for long-term storage.
2. Update transformation records and vector maps.

6. Abbreviations

• SOP: Standard Operating Procedure
• SOC: Super Optimal Broth with Catabolite Repression
• cfu: Colony Forming Units

7. Documents

1. Transformation Logbook (Annexure-1)
2. Glycerol Stock Record (Annexure-2)

8. References

• ICH Q5D: Cell Substrate Derivation and Characterization
• WHO TRS 978 – Annex on Recombinant DNA Technology
• CDSCO R&D Laboratory Guidelines

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Transformation Logbook

Annexure-2: Glycerol Stock Record

Revision History:

Standard Operating Procedure for Plasmid Amplification and Purification in Biosimilar Development

1. Purpose

To define the process for amplifying and purifying plasmid DNA from transformed bacterial cells to ensure high-quality DNA yield suitable for downstream biosimilar applications.

2. Scope

This SOP applies to research personnel in the Biosimilars department involved in plasmid preparation for gene expression, cloning, and sequence verification activities.

3. Responsibilities

• Research Associate: Executes bacterial growth and plasmid extraction.
• Laboratory Technician: Prepares media, stocks, and handles centrifugation and filtration steps.
• QA Officer: Reviews purity and concentration documentation.

4. Accountability

The Head of Biosimilars Molecular Biology is accountable for ensuring plasmid preparation is carried out per defined standards and the DNA meets required specifications.

5. Procedure

5.1 Inoculation and Culture

1. Inoculate a single colony of transformed E. coli into 5 mL of LB broth with appropriate antibiotic.
2. Incubate at 37°C with shaking (200 rpm) overnight.

5.2 Plasmid Amplification

1. Transfer overnight culture into 100 mL LB broth with antibiotic.
2. Incubate at 37°C with shaking for 8–10 hours until OD₆₀₀ reaches 2.0–2.5.

5.3 Harvesting Bacterial Cells

1. Transfer culture to centrifuge bottles and spin at 6,000 rpm for 10 minutes at 4°C.
2. Discard supernatant and proceed with plasmid extraction immediately or store pellet at -20°C.

5.4 Plasmid Purification

1. Use a commercial plasmid purification kit (e.g., Qiagen, Thermo Fisher).
2. Follow standard alkaline lysis procedure:
   • Resuspend in Buffer P1
   • Lyse with Buffer P2
   • Neutralize with Buffer N3
3. Centrifuge at 13,000 rpm for 10 minutes to pellet debris.
4. Apply supernatant to spin column and wash with ethanol-based buffer.
5. Elute plasmid in nuclease-free water or TE buffer (50–100 µL).

5.5 DNA Quantification and Quality Check

1. Measure DNA concentration using NanoDrop or equivalent spectrophotometer.
2. Check purity using A₂₆₀/A₂₈₀ ratio (acceptable: 1.8–2.0).
3. Record all data in Plasmid Quality Log (Annexure-1).

5.6 Agarose Gel Verification

1. Run 5 µL of plasmid DNA on 1% agarose gel with loading dye.
2. Visualize bands under UV transilluminator.
3. Confirm correct plasmid size and supercoiled form.

5.7 Documentation and Storage

1. Label purified plasmid tubes with ID, date, and concentration.
2. Store at -20°C or -80°C depending on long-term use.
3. Update Plasmid Storage Inventory (Annexure-2).

6. Abbreviations

• SOP: Standard Operating Procedure
• OD₆₀₀: Optical Density at 600 nm
• TE: Tris-EDTA Buffer
• QA: Quality Assurance

7. Documents

1. Plasmid Quality Log (Annexure-1)
2. Plasmid Storage Inventory (Annexure-2)

8. References

• ICH Q5B – Analysis of Expression Constructs
• WHO Technical Report Series 978 – Annex on DNA Products
• CDSCO Guidelines for Molecular Biology Procedures

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Plasmid Quality Log

Annexure-2: Plasmid Storage Inventory

Revision History:

Standard Operating Procedure for Restriction Enzyme Digestion and Mapping in Biosimilar Research

1. Purpose

To establish a standard method for performing restriction enzyme digestion and mapping of plasmid DNA for verification of insert orientation, integration, and overall vector integrity during biosimilar development.

2. Scope

This SOP applies to the Biosimilars R&D team engaged in molecular biology operations involving plasmid validation post-cloning and prior to expression studies.

3. Responsibilities

• Molecular Biologist: Designs digestion strategy, selects appropriate enzymes, and interprets results.
• Research Assistant: Prepares reaction mixes and performs electrophoresis.
• QA Personnel: Verifies documentation of mapping results and digestion patterns.

4. Accountability

The Head of Molecular Biology is accountable for ensuring all plasmid digestion and mapping procedures are compliant with molecular verification protocols and documented accordingly.

5. Procedure

5.1 Selection of Restriction Enzymes

1. Choose enzymes based on:
   • Vector backbone map
   • Insert flanking regions
   • Expected fragment sizes
2. Use double or single digests as needed to differentiate between orientations or configurations.

5.2 Preparation of Digestion Reaction

1. Prepare the reaction mix in a sterile microcentrifuge tube:
   • Plasmid DNA: 500–1000 ng
   • 10X Buffer: 2 µL
   • Restriction Enzyme(s): 1 µL each
   • Nuclease-Free Water: To make up to 20 µL
2. Gently mix by tapping and spin down briefly.
3. Incubate at 37°C for 1–2 hours (as per enzyme manufacturer guidelines).

5.3 Agarose Gel Electrophoresis

1. Prepare 1% or 1.5% agarose gel with safe DNA stain (e.g., ethidium bromide or SYBR Safe).
2. Load 5 µL of digested sample mixed with 1 µL of 6X loading dye.
3. Include 1 kb or 100 bp DNA ladder as reference.
4. Run gel at 80–100V for 45–60 minutes in 1X TAE buffer.
5. Visualize bands using UV transilluminator and photograph gel for records.

5.4 Mapping and Result Interpretation

1. Compare observed bands with predicted digestion pattern from in-silico map (e.g., SnapGene or NEBcutter).
2. Record:
   • Fragment sizes
   • Band intensity
   • Lane and ladder references
3. Document findings in Plasmid Mapping Record (Annexure-1).

5.5 Troubleshooting and Repeat Analysis

1. If unexpected bands appear:
   • Check for star activity or incomplete digestion.
   • Repeat with fresh enzyme or alternative buffer.
   • Use additional enzymes to confirm map.

5.6 Documentation and Archiving

1. Label gel image with date, sample ID, and enzyme names.
2. Attach to printed mapping report and file in project record folder.
3. Store digital copy in central repository with access control.

6. Abbreviations

• SOP: Standard Operating Procedure
• TAE: Tris Acetate EDTA Buffer
• QA: Quality Assurance

7. Documents

1. Plasmid Mapping Record (Annexure-1)
2. Gel Image Archive Log (Annexure-2)

8. References

• ICH Q5B – Expression Construct Analysis
• WHO Guidelines on DNA-Based Biologics
• CDSCO Recombinant Product Evaluation Manual

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Plasmid Mapping Record

Annexure-2: Gel Image Archive Log

Revision History:

Standard Operating Procedure for Agarose Gel Electrophoresis in Biosimilar R&D

1. Purpose

To establish a standardized procedure for performing agarose gel electrophoresis to separate, identify, and analyze DNA fragments for plasmid confirmation and molecular biology workflows in biosimilar development.

2. Scope

This SOP applies to all R&D personnel involved in analyzing plasmid DNA, PCR products, and restriction digests through agarose gel electrophoresis within the Biosimilars department.

3. Responsibilities

• Research Assistant: Prepares gel, loads samples, runs electrophoresis, and documents results.
• Lab Technician: Maintains electrophoresis equipment and ensures buffer/media quality.
• QA Representative: Reviews gel documentation for completeness and compliance.

4. Accountability

The Head of Molecular Biology is accountable for ensuring that electrophoresis procedures are performed safely, reproducibly, and in accordance with molecular characterization protocols.

5. Procedure

5.1 Materials Required

• Agarose powder
• 1X TAE or TBE buffer
• DNA ladder (100 bp or 1 kb)
• DNA samples (e.g., plasmids, PCR products)
• 6X Loading dye
• DNA stain (e.g., Ethidium Bromide, SYBR Safe)
• Gel casting tray and comb, electrophoresis tank, power supply

5.2 Gel Preparation

1. Weigh 1 g agarose for a 1% gel in 100 mL 1X TAE buffer (adjust for volume/concentration as needed).
2. Microwave gently until agarose dissolves completely (clear solution).
3. Cool to ~55°C, add DNA stain as per manufacturer’s instructions.
4. Pour gel into casting tray with comb in place. Allow to solidify (20–30 minutes).

5.3 Sample Preparation

1. Mix DNA samples (2–5 µL) with 6X loading dye (1 µL).
2. Centrifuge briefly to collect contents at the bottom of the tube.

5.4 Gel Electrophoresis

1. Place the solidified gel into the electrophoresis tank and cover with 1X TAE buffer.
2. Carefully load samples and DNA ladder into wells.
3. Connect electrodes (black to negative, red to positive) and run at 80–120 V for 45–60 minutes.

5.5 Visualization and Documentation

1. Turn off power, remove gel, and visualize under UV or blue-light transilluminator.
2. Capture gel image with gel documentation system.
3. Label image with gel number, date, DNA IDs, ladder type, and voltage used.
4. Attach image to Gel Electrophoresis Log (Annexure-1).

5.6 Cleanup and Waste Disposal

1. Dispose of used gels and staining agents per biosafety waste guidelines.
2. Wipe down the tank and tray using 70% ethanol or suitable lab disinfectant.

6. Abbreviations

• SOP: Standard Operating Procedure
• TAE: Tris-Acetate-EDTA
• TBE: Tris-Borate-EDTA
• QA: Quality Assurance

7. Documents

1. Gel Electrophoresis Log (Annexure-1)
2. Gel Documentation Record (Annexure-2)

8. References

• ICH Q5B – Analysis of Expression Constructs
• WHO Guidelines on Molecular Techniques for DNA Products
• CDSCO Manual on Molecular Biology Practices

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Gel Electrophoresis Log

Annexure-2: Gel Documentation Record

Revision History:

Standard Operating Procedure for Transient Transfection Methods in Biosimilar R&D

1. Purpose

To define the procedure for transient transfection of mammalian cells using lipid-mediated or electroporation techniques for the expression of biosimilar proteins in early-stage R&D experiments.

2. Scope

This SOP applies to personnel involved in biosimilar R&D who perform gene delivery into cell lines like CHO, HEK293, or others for temporary expression analysis and protein production.

3. Responsibilities

• Research Scientist: Plans and executes the transfection experiment and analyzes protein expression.
• Lab Assistant: Prepares media, buffers, and ensures cell viability.
• QA Officer: Reviews transfection logs and performance documentation.

4. Accountability

The Head of Cell Culture and Expression Systems is accountable for ensuring the transfection protocols meet reproducibility and compliance standards.

5. Procedure

5.1 Cell Preparation

1. Culture cells (e.g., HEK293 or CHO) in appropriate media until they reach 70–90% confluency.
2. Use fresh, healthy cells between passages 5–20.
3. Count cells using a hemocytometer or cell counter and adjust to required density (e.g., 2 × 10⁵ cells/mL).

5.2 Lipid-Mediated Transfection Protocol

1. In a sterile tube, dilute 1 µg plasmid DNA in 50 µL of serum-free DMEM or Opti-MEM.
2. In a separate tube, dilute 2 µL of transfection reagent (e.g., Lipofectamine 3000) in 50 µL of the same medium.
3. Combine the two solutions, mix gently, and incubate at room temperature for 10–15 minutes.
4. Add the mixture dropwise to cells plated in a 24-well or 6-well plate.
5. Incubate at 37°C with 5% CO₂ for 24–72 hours.

5.3 Electroporation Protocol

1. Harvest 1 × 10⁶ cells and resuspend in 100 µL of electroporation buffer.
2. Add 2–5 µg of plasmid DNA to the cell suspension.
3. Transfer mixture into pre-chilled electroporation cuvette (2 mm gap).
4. Electroporate using program settings recommended for the specific cell type (e.g., 250 V, 950 µF).
5. Immediately transfer cells to recovery medium in a culture plate.

5.4 Expression Analysis

1. Harvest cells or media after 48–72 hours depending on the target protein.
2. Analyze expression using ELISA, SDS-PAGE, Western blot, or flow cytometry as applicable.
3. Record data in Transfection and Expression Log (Annexure-1).

5.5 Documentation and Storage

1. Label transfected samples with cell line, plasmid ID, and transfection date.
2. Store samples at -20°C or -80°C based on protein stability.
3. File all experiment sheets, instrument settings, and results in the R&D archive.

6. Abbreviations

• SOP: Standard Operating Procedure
• CHO: Chinese Hamster Ovary
• HEK: Human Embryonic Kidney
• ELISA: Enzyme-Linked Immunosorbent Assay
• DMEM: Dulbecco’s Modified Eagle Medium

7. Documents

1. Transfection and Expression Log (Annexure-1)
2. Cell Culture Condition Sheet (Annexure-2)

8. References

• ICH Q5D – Derivation and Characterization of Cell Substrates
• WHO Guidelines for Recombinant DNA Product Expression
• CDSCO Technical Guidelines on Cell-Based Expression Systems

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Transfection and Expression Log

Annexure-2: Cell Culture Condition Sheet

Revision History:

Standard Operating Procedure for Selection of Stably Transfected Clones in Biosimilar R&D

1. Purpose

To define the process for selecting, isolating, and expanding stably transfected mammalian cell clones that integrate the gene of interest for long-term expression of biosimilar proteins.

2. Scope

This SOP applies to biosimilar R&D teams involved in generating stable cell lines for protein expression in systems such as CHO or HEK293 cells.

3. Responsibilities

• Research Scientist: Designs and executes selection strategy and performs screening assays.
• Lab Technician: Prepares selection medium and maintains cell cultures.
• QA Officer: Reviews clone data and ensures documentation integrity.

4. Accountability

The Head of Cell Line Development is accountable for ensuring stable clone selection complies with regulatory expectations and technical quality standards.

5. Procedure

5.1 Post-Transfection Recovery

1. Allow cells 24–48 hours of recovery in complete media post-transfection.
2. Monitor confluency and viability daily.

5.2 Antibiotic Selection

1. Prepare selection medium containing appropriate antibiotic (e.g., G418, Hygromycin, Puromycin) based on plasmid resistance marker.
2. Perform kill curve prior to experiment to determine minimum lethal dose.
3. Replace recovery medium with selection medium and incubate under standard conditions (e.g., 37°C, 5% CO₂).
4. Continue selection for 10–14 days until only resistant colonies remain.

5.3 Cloning and Isolation

1. Pick individual colonies manually using sterile pipette tips or cloning rings.
2. Transfer to 24-well plates containing selection media and incubate for 5–7 days.
3. Expand viable clones into larger wells or flasks gradually.

5.4 Screening for Expression

1. Harvest culture supernatant or cell lysate from expanded clones.
2. Evaluate expression levels using:
   • ELISA for secreted proteins
   • SDS-PAGE and Western blot for intracellular or membrane proteins
   • qPCR for gene copy number
3. Document findings in Clone Screening Log (Annexure-1).

5.5 Cryopreservation of Positive Clones

1. Select top-performing clones with stable expression.
2. Freeze vials using freezing media (10% DMSO in FBS or serum-free alternative).
3. Label with Clone ID, date, and passage number.
4. Store in -80°C initially, then transfer to liquid nitrogen for long-term storage.

5.6 Documentation and Records

1. Maintain complete records for each clone including origin, passage history, antibiotic used, expression data, and storage location.
2. Update Stable Clone Master Record (Annexure-2).

6. Abbreviations

• SOP: Standard Operating Procedure
• CHO: Chinese Hamster Ovary
• FBS: Fetal Bovine Serum
• ELISA: Enzyme-Linked Immunosorbent Assay
• DMSO: Dimethyl Sulfoxide

7. Documents

1. Clone Screening Log (Annexure-1)
2. Stable Clone Master Record (Annexure-2)

8. References

• ICH Q5D – Cell Substrates Used for Production
• WHO Guidelines for Cell Line Characterization
• CDSCO Handbook on Biologics

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Clone Screening Log

Annexure-2: Stable Clone Master Record

Revision History: